HOME >> BIOLOGY >> NEWS
Experimental appetite suppressant affects numerous brain messengers in mice

Johns Hopkins scientists report success in figuring out how an experimental compound prevents mice from recognizing that it's time to eat, profoundly suppressing appetite and causing weight loss.

The compound, called C75, alters the natural balance of brain messengers that normally send signals of hunger during fasting and of satiety when full. In both lean and obese mice, C75 affects those signals, according to a report on the work in the Dec. 26 online version of the Proceedings of the National Academy of Sciences.

Obesity in humans is a major public health problem and is linked to a heightened risk of developing diabetes, stroke and heart disease. While mice are not men, there are common pathways in fundamental activities.

"If we can understand the pathway that triggers eating, we may be able to find safe ways to intervene," says Daniel Lane, Ph.D., professor of biological chemistry in the School of Medicine's Institute for Basic Biomedical Sciences. "We're close to figuring out how these neurotransmitters are connected, at least in mice, and what really affects their expression."

Building on the knowledge that C75 blocks the enzyme fatty acid synthase, which helps the body store energy, Lane and others last year reported that mice given C75 stopped eating and lost about 5 percent of their body weight in just a day.

In the new study of lean (normal) mice and mice genetically engineered to be obese, the scientists looked for changes in the appetite signals in animals that fasted for one day and those injected with C75. While neither group ate, mice injected with C75 had more of the "satisfied" signals and less of the "hungry" signals than other mice.

Normally, fasting dramatically increases the amounts of two neurotransmitters, AgRP and NPY. Coming from neurons in a particular area of the hypothalamus, a small structure inside the brain, these messengers tell the animal to eat. When f
'"/>

Contact: Joanna Downer
jdowner1@jhmi.edu
410-614-5105
Johns Hopkins Medical Institutions
8-Jan-2002


Page: 1 2 3

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. Experimental therapy stops allergic reactions in mice

Post Your Comments:
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
(Date:10/25/2014)... 2014 Today, Nerium International, a leader ... of its “Reflect Your Youth” contest, an effort launched ... a difference in their skin since using Nerium’s product ... on life as a result of their newfound confidence. ... effort by Nerium International to inspire conversations focused on ...
(Date:10/25/2014)... , October 24, 2014 Oramed ... pharmaceutical company focused on the development of oral drug ... Nadav Kidron will present at FireRock Capital,s Micro-Cap ... Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: ... New York City , ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
Cached News: